Pre-clinical evaluation of Rimeporide, an inhibitor of the sodium/proton exchanger type 1, for Duchenne muscular dystrophy, a fatal genetic disorder of chidhood onset

• Research unit: INNOSUISSE
• Project number: 16065.1;5 PFLS-LS

Short description (English)

Pre-clinical evaluation of Rimeporide, an inhibitor of the sodium/proton exchanger type 1, for Duchenne muscular dystrophy, a fatal genetic disorder of chidhood onset

Short description (French)

Pre-clinical evaluation of Rimeporide, an inhibitor of the sodium/proton exchanger type 1, for Duchenne muscular dystrophy, a fatal genetic disorder of chidhood onset

Abstract (English)

EspeRare is a Swiss NPO skilled in drug development and program leadership for rare diseases. It is aiming at performing the pre-clinical validation of Rimeporide to treat Duchenne Muscular Dystrophy (DMD), a debilitating muscular disorder for which no cure exists. This project will generate data to obtain Orphan Designation and to initiate clinical trials. If successful, Rimeporide has an estimated peak sales of ca. 160M$/y by 2025. This project combines the expertise of EspeRare to the skills of UNIGE in pharmacotherapy and preclinical trials for DMD.

Abstract (French)

EspeRare is a Swiss NPO skilled in drug development and program leadership for rare diseases. It is aiming at performing the pre-clinical validation of Rimeporide to treat Duchenne Muscular Dystrophy (DMD), a debilitating muscular disorder for which no cure exists. This project will generate data to obtain Orphan Designation and to initiate clinical trials. If successful, Rimeporide has an estimated peak sales of ca. 160M$/y by 2025. This project combines the expertise of EspeRare to the skills of UNIGE in pharmacotherapy and preclinical trials for DMD.